1 / 30

The Changing Therapeutic Landscape of CINV

The Changing Therapeutic Landscape of CINV. Program Goals. Preventing CINV: Why Do We Need New Agents?. Emetogenicity of Chemotherapy. Antiemetic Guidelines Current Recommendations for Patients Receiving HEC. Antiemetic Guidelines Current Recommendations for Patients Receiving MEC.

candida-larry
Download Presentation

The Changing Therapeutic Landscape of CINV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Changing Therapeutic Landscape of CINV

  2. Program Goals

  3. Preventing CINV: Why Do We Need New Agents?

  4. Emetogenicity of Chemotherapy

  5. Antiemetic GuidelinesCurrent Recommendations for Patients Receiving HEC

  6. Antiemetic GuidelinesCurrent Recommendations for Patients Receiving MEC

  7. Preventing CINV: Why Do We Need New Agents? (cont)

  8. Evidence That Guideline-based Care Is Effective in the Prevention of CINV

  9. New Antiemetic Agents and Formulations

  10. Aprepitant: Drug-Drug Interactions

  11. Rolapitant: Drug-Drug Interactions

  12. Rolapitant in Patients Receiving MECPhase 3 Study Design

  13. Rolapitant in Patients Receiving MECEfficacy Results

  14. Rolapitant in Patients Receiving MECSafety

  15. NEPA + DEX vs Oral PALO + DEX in AC-based MECMultinational, Randomized, Double-blind Phase 3 Study

  16. NEPA + DEX vs PALO + DEX in AC-based MECCR Rates (cycle 1)

  17. NEPA + DEX vs Oral PALO + DEX in AC-based MECOverall CR Rates Across Multiple Cycles

  18. NEPA + DEX vs PALO + DEX in AC-Based MECSafety Across Multiple Cycles

  19. NEPA + DEX vs PALO + DEX in AC-based MECMost Common TRAEs Across Multiple Cycles

  20. The Problem of Nausea

  21. Summary

  22. Abbreviations

  23. Abbreviations (cont)

  24. References

  25. References (cont)

  26. References (cont)

  27. References (cont)

  28. References (cont)

  29. References (cont)

  30. References (cont)

More Related